1. Home
  2. GH vs OKTA Comparison

GH vs OKTA Comparison

Compare GH & OKTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Guardant Health Inc.

GH

Guardant Health Inc.

HOLD

Current Price

$85.12

Market Cap

13.3B

Sector

Health Care

ML Signal

HOLD

Logo Okta Inc.

OKTA

Okta Inc.

HOLD

Current Price

$78.61

Market Cap

15.0B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
GH
OKTA
Founded
2011
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
13.3B
15.0B
IPO Year
2018
2017

Fundamental Metrics

Financial Performance
Metric
GH
OKTA
Price
$85.12
$78.61
Analyst Decision
Strong Buy
Buy
Analyst Count
20
38
Target Price
$117.80
$105.19
AVG Volume (30 Days)
1.7M
3.4M
Earning Date
04-29-2026
03-04-2026
Dividend Yield
N/A
N/A
EPS Growth
6.74
2083.33
EPS
N/A
1.31
Revenue
$982,021,000.00
$2,919,000,000.00
Revenue This Year
$33.40
$11.24
Revenue Next Year
$28.55
$9.39
P/E Ratio
N/A
$61.53
Revenue Growth
32.88
11.84
52 Week Low
$36.36
$68.77
52 Week High
$120.74
$127.52

Technical Indicators

Market Signals
Indicator
GH
OKTA
Relative Strength Index (RSI) 34.90 48.18
Support Level $82.26 $75.70
Resistance Level $103.16 $82.49
Average True Range (ATR) 3.94 3.27
MACD 0.07 0.65
Stochastic Oscillator 20.02 68.53

Price Performance

Historical Comparison
GH
OKTA

About GH Guardant Health Inc.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

About OKTA Okta Inc.

Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.

Share on Social Networks: